Analyst firms · Leerink Partners · RAPT
Leerink Partners RAPT price target and rating history
RAPT Therapeutics Inc. (RAPT) · Health Care
Leerink Partners rates RAPT Therapeutics Inc. (RAPT) Outperform with a $37 price target, as of its latest action on Sep 26, 2025. It has published 3 rating actions on RAPT since August 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Outperform
- Price target
- $37
- Median target, all firms
- Too few
- Actions on RAPT
- 3
Leerink Partners price target on RAPT
Every Leerink Partners rating on RAPT
- Sep 26, 2025
- Feb 21, 2024
- Aug 12, 2021
Questions about Leerink Partners and RAPT
- What is Leerink Partners's price target for RAPT?
- Leerink Partners's latest stated price target for RAPT Therapeutics Inc. (RAPT) is $37, from its action on Sep 26, 2025.
- What is Leerink Partners's rating on RAPT?
- Leerink Partners rates RAPT Outperform, a bullish rating, as of Sep 26, 2025.
- When did Leerink Partners last change its view on RAPT?
- On Sep 26, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $37.
More RAPT rating histories
All Leerink Partners ratingsRAPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.